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Abstract
Background:  Dietary isothiocyanates (ITCs) are electrophilic compounds that have diverse
biological activities including induction of apoptosis and effects on cell cycle. They protect against
experimental carcinogenesis in animals, an activity believed to result from the transcriptional
induction of "Phase 2" enzymes. The molecular mechanism of action of ITCs is unknown. Since
ITCs are electrophiles capable of reacting with sulfhydryl groups on amino acids, we hypothesized
that ITCs induce their biological effects through covalent modification of proteins, leading to
changes in cell regulatory events. We previously demonstrated that stress-signaling kinase
pathways are inhibited by other electrophilic compounds such as menadione. We therefore tested
the effects of nutritional ITCs on MEKK1, an upstream regulator of the SAPK/JNK signal
transduction pathway.
Methods: The activity of MEKK1 expressed in cells was monitored using in vitro kinase assays to
measure changes in catalytic activity. The activity of endogenous MEKK1, immunopurified from ITC
treated and untreated LnCAP cells was also measured by in vitro kinase assay. A novel labeling and
affinity reagent for detection of protein modification by ITCs was synthesized and used in
competition assays to monitor direct modification of MEKK1 by ITC. Finally, immunoblots with
phospho-specific antibodies were used to measure the activity of MAPK protein kinases.
Results: ITCs inhibited the MEKK1 protein kinase in a manner dependent on a specific cysteine
residue in the ATP binding pocket. Inhibition of MEKK1 catalytic activity was due to direct, covalent
and irreversible modification of the MEKK1 protein itself. In addition, ITCs inhibited the catalytic
activity of endogenous MEKK1. This correlated with inhibition of the downstream target of MEKK1
activity, i.e. the SAPK/JNK kinase. This inhibition was specific to SAPK, as parallel MAPK pathways
were unaffected.
Conclusion: These results demonstrate that MEKK1 is directly modified and inhibited by ITCs,
and that this correlates with inhibition of downstream activation of SAPK. These results support
the conclusion that ITCs may carry out many of their actions by directly targeting important cell
regulatory proteins.
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Background
The MEKK1 protein kinase is a critical upstream mediator
in signaling pathways that control the response of cells to
stress stimuli. It directly phosphorylates and activates the
SEK1 protein kinase, leading to activation of the stress
activated protein kinase/jun N terminal kinase (SAPK/
JNK) [1,2]. By virtue of its participation in this pathway,
MEKK1 is involved in cellular responses to hyperosmotic
shock, DNA damage and inflammatory cytokines [3,4]. It
has also been characterized for its dual role in apoptosis
signaling, contributing either a cell survival signal or a
pro-apoptotic signal, depending on the form of the pro-
tein that predominates.
MEKK1 is a large protein kinase [5] with activity that is
regulated by multiple diverse means including phosphor-
ylation and proteolytic cleavage [6-9]. In addition, we
recently demonstrated that MEKK1 is inhibited by oxida-
tive stress stimuli through a mechanism involving direct
glutathionylation of a specific cysteine residue in the ATP
binding pocket [10]. This thiol modification is reversible
by reducing agents, including glutathione, in vitro, and
likely represents a reversible means of inhibiting the
kinase activity within the cell during the response to oxi-
dative insult.
The reactive cysteine in the ATP binding pocket of MEKK1
is quite unique among protein kinases. In an effort to
identify cysteine reactive compounds that might likewise
inhibit MEKK1 by targeting this residue, we considered
physiologic agents that could result in protein modifica-
tion on cysteine. One such group of compounds is the iso-
thiocyanate (ITC) class of dietary chemopreventives, that
have established roles in apoptosis and prevention of can-
cer, (for reviews, see [11-13]), processes in which MEKK1
has been implicated. These chemicals are abundant in
members of the kale family, such as broccoli, and human
studies have shown that consumption of broccoli sprouts
can result in circulating levels of ITCs in the low micromo-
lar range [14].
Cancer chemoprevention by ITCs has been attributed to
their ability to induce gene expression of a family of
enzymes involved in detoxification and excretion of car-
cinogens, the Phase 2 genes [13]. However, this activity is
insufficient to explain the ability of ITCs to induce growth
arrest and apoptosis in tumor cells [15,16], to reduce tum-
origenesis even if administered after the carcinogen
[17,18], and to prevent tumor growth in xenograft models
[19-21]. Instead, these results suggest that the ITCs may
function by direct control of cell growth or death path-
ways.
The nature of the direct molecular target(s) of ITCs within
cells has not been resolved. We reasoned that ITCs, being
electrophilic compounds, could decorate cell regulatory
proteins through stable covalent modification of cysteine
or lysine residues, and that these targets could be identi-
fied using an affinity-labeled variant of nutritional ITCs.
We tested this hypothesis on MEKK1, since the SAPK/JNK
pathway that is regulated by MEKK1 has been implicated
in apoptosis and cell growth, processes that are also
impacted by ITCs.
We describe here results that indicate that nutritional iso-
thiocyanates are able to covalently and irreversibly inhibit
MEKK1. This inhibition is specific to MEKK1 and not to a
closely related kinase, and occurs through covalent modi-
fication requiring a single cysteine in ATP binding pocket.
Methods
Chemicals and antibodies
Unless otherwise specified, all chemicals were obtained
from Sigma-Aldrich. The Streptavidin-HRP detection rea-
gent was from Zymed. N,N-dimethylformamide (DMF)
and tetrahydrofuran (THF) were obtained from OptiDry
canisters (<50 ppm H2O, Fisher Scientific). THF was
passed through an activated alumina (activity I) column
before use. DMF, MeCN (99.8% anhydrous; Aldrich; Mil-
waukee, WI), and chloroform were used without further
drying. Norbiotinamine hydrochloride (Molecular
Probes; Eugene, OR), EZ-Link™ 5-(biotinamido)-
pentylamine (Pierce Biotechnology; Rockford, IL) were
purchased and used as obtained. All other reagents,
including 1,1'-thiocarbonyldi-2,2'-pyridone (TCDP),
were purchased from Aldrich and used as obtained.
Plasmids
MEKK1 and ASK1 plasmids and the C1238V mutant have
been previously described [10].
Cell Culture, Transfections and Treatments
LNCaP cells were grown in RPMI with 10% fetal bovine
serum and penicillin/streptomycin antibiotics. For analy-
sis of endogenous MEKK1, cells were serum starved for 18
hours prior to treatment. HeLa and CV-1 cells were grown
in DMEM with 10% calf serum and penicillin/streptomy-
cin antibiotics. For immunoblotting of active MAPKs, the
cells were serum starved for 18 hours prior to treatment.
Expression of proteins was accomplished using the T7-
polymerase-driven vaccinia virus overexpression system
[22] as previously described [10]. After overnight incuba-
tion, the cells were treated with isothiocyantes at the con-
centrations indicated in the figure legends for 20–30
minutes, then lysed for in vitro kinase assays or labeling
reactions as described below.
In vitro kinase assays
Following treatment, cells were lysed in MOPS lysis buffer
(50 mM MOPS pH 7.0, 250 mM NaCl, 5 mM EDTA, 0.1%BMC Cancer 2007, 7:183 http://www.biomedcentral.com/1471-2407/7/183
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NP-40) supplemented with 2.5 µg/ml aprotinin, 2.5 µg/
ml leupeptin, 10 mM sodium fluoride, 5 mM sodium
pyrophosphate, 1 mM sodium orthovanadate, and 10
mM β glycerolphosphate. Lysates were clarified at 14,000
× g for 5 minutes in a microcentrifuge. CBD-tagged pro-
teins were purified using chitin beads (New England
Biolabs). The beads were washed 3 times with MLB, then
once with 50 mM Tris/HCl (pH7.4). In some experiments,
purified proteins were treated with isothiocyanates in
vitro, in 50 mM Tris/HCl (pH7.4). Beads were then
washed to remove isothiocyanates prior to kinase assay.
Kinase assays were carried out in a buffer containing 50
mM Tris (pH7.4), 10 mM magnesium chloride, and 7.5
µM ATP in the presence of 10 µCi gamma32P-ATP. One µg
of bacterially-expressed GST-tagged catalytically inactive
SEK (GST SEK-KR) was used as substrate and the reactions
were incubated for 30 minutes at room temperature.
Kinase assays were stopped by addition of an equal vol-
ume of 2× Laemmli sample buffer (2% SDS, 100 mM Tris
(pH 7.0), 20% Glycerol, 150 mM DTT, Bromophenol
Blue), and then boiled and electrophoresed on SDS-PAGE
(10%). Gels were transferred to PVDF (Immobilon) and
imaged for quantification using a Packard Instant Imager.
Equivalent protein was confirmed by immunoblotting
with anti-MEKK1 (Santa Cruz Biotechnology).
Synthesis of Bio-ITC [4-(4-Isothiocyanato-butyl)-
tetrahydro-thieno[3,4-d]imidazol-2-one]
A solution of norbiotinamine hydrochloride (10 mg,
0.040 mmol) dissolved in acetonitrile (2 mL) and chloro-
form (0.40 mL) was prepared in a flame dried flask under
Ar(g). A solution of TCDP (10 mg, 0.040 mmol) in chloro-
form (0.40 mL) was added to the previously prepared
solution. Following 15 minutes of continued stirring, one
drop of triethylamine was added. The yellow-orange color
was diminished upon addition. After 45 minutes, an addi-
tional drop of triethylamine was added and the reaction's
progress was followed by thin layer chromatography
(TLC). After four hours, the starting material was con-
sumed and the reaction was concentrated to a crude mate-
rial that was purified by normal phase preparative-TLC
(Silica Gel GF®, 500 microns, Analtech) using 1:9 metha-
nol/chloroform as an eluent. Following separation, the
desired band was carefully isolated from the plate and
washed through a fritted funnel with multiple portions of
ethyl acetate. The organic solvent was concentrated to 7
mG (70%) of the title compound as a off-white powdery
solid. Rf (10% MeOH in CHCl3) = 0.22. 1H NMR (300
MHz, CD3OD, 23°C, δ): 4.50 (dd, J = 7.9, 5.1 Hz, 1 H),
4.33 (dd, J = 7.1, 4.5 Hz, 1 H), 3.58 (t, J = 6.5 Hz, 2 H),
2.95 (dd, J = 12.8, 5.1 Hz, 1 H), 2.72 (d, J = 12.8 Hz, 1 H),
1.83–1.52 (m, 6 H) ppm. 13C NMR (300 MHz, CD3OD,
23°C,  δ): 168.30, 125.85, 63.41, 61.63, 56.90, 41.05,
31.00, 29.08, 27.33 ppm. MS (ESI+) m/z 258 [M+H]+.
BioITC labeling reactions
Untreated or PEITC treated cells were lysed in Tris lysis
buffer (50 mM Tris pH7.8, 0.1% NP-40) supplemented
with 2.5 µg/ml aprotinin and 2.5 µg/ml leupeptin. Lysates
were clarified by centrifugation at 14,000 × g for 5 min-
utes. Clarified lysates were reacted with 500 µM Bio-ITC
for 30 minutes at room temperature. Samples were
removed for in vitro kinase assay, cell lysate immunob-
lots, and/or chitin bead purification and immunoblot
analysis, as indicated in the figure legends.
Analysis of MAPK pathways
HeLa cells were seeded in 6 well plates and then serum
starved overnight. PEITC at concentrations of 200 µM to
12.5 µM (in two fold serial dilutions) was added to the
media and the cells incubated for 7 minutes at 37°C.
Sorbitol was then added to 400 mM to induce hyperos-
motic stress, and the incubation continued for an addi-
tional 20 minutes. Cells were lysed in 500 µL MLB, and
200 µL used to prepare a whole cell lysate by adding 50 µL
of 5× Laemmli sample buffer. Samples were analyzed by
immunoblotting using antibodies directed against phos-
phorylated forms of various MAPK family members as
described in the figure legend.
Results
ITCs inhibit MEKK1, but not the related protein kinase 
ASK1, in intact cells
To determine the effect of isothiocyanates on MEKK1
activity, we expressed a full-length MEKK1 protein fused
to a chitin binding domain (CBD) tag to allow purifica-
tion of the protein by binding to chitin beads. In parallel,
we expressed the related related MAPK3K, the Apoptosis
Signal-regulating Kinase (ASK1), bearing the same car-
boxy-terminal CBD tag. The cells were treated with
increasing concentrations of phenethyl isothiocyanate
(PEITC), and each kinase was purified by affinity chroma-
tography using chitin beads followed by in vitro kinase
assay using a bacterially-expressed inactive mutant of SEK
(SEK-KR) as substrate. Treatment of intact cells with
PEITC inhibited MEKK1 in a dose dependent fashion
within 30 minutes of exposure (Figure 1, left panel). In
contrast, ASK1 was not inhibited by PEITC treatment,
even at the highest concentrations (Figure 1, right panel),
demonstrating a specific mechanism of inhibition of
MEKK1 by PEITC. We observed inhibition of MEKK1 by
other ITCs that have been implicated in cancer chemopre-
vention, including sulforaphane, at similar concentra-
tions (not shown).
Inhibition of MEKK1 by PEITC is direct and requires 
cysteine 1238
We previously identified a cysteine residue in the ATP
binding pocket of MEKK1 that is glutathionylated during
oxidative stress, resulting in inhibition of the kinase [10].BMC Cancer 2007, 7:183 http://www.biomedcentral.com/1471-2407/7/183
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We compared the inhibition of the wild type catalytic
domain fragment of MEKK1 to the effect of ITCs on a
mutant MEKK1 protein in which C1238 has been
mutated to valine. The C1238V mutant retains full wild
type activity and is not inhibited by oxidative stress stim-
uli. PEITC dose dependently inhibited the wild type cata-
lytic fragment (Figure 2A, top panel). However, the
C1238V mutant was completely resistant to treatment
with PEITC (Figure 2A, bottom panel). Thus, inhibition of
MEKK1 by PEITC requires the cysteine residue at position
1238.
To determine whether inhibition of MEKK1 is due to
direct modification of MEKK1 and not an effect on
another member of the signaling pathway, we examined
the sensitivity of purified MEKK1 to PEITC treatment in
vitro. CBD-tagged wild type MEKK1 or the C1238V
mutant were expressed in cells, purified on chitin beads
and then treated with PEITC in vitro. As observed in exper-
iments with intact cells, wild type MEKK1 was inhibited
by PEITC treatment in a dose dependent manner, while
the C1238V mutant was completely resistant to PEITC
treatment (Figure 2B). This demonstrates that inhibition
of MEKK1 by PEITC is due to a direct effect on the kinase
itself, and not due to inhibition of another component of
the signaling pathway.
MEKK1 is protected from PEITC inhibition by an ATP 
analog
Since C1238 is within the ATP binding domain of
MEKK1, we suspected that occupancy of the ATP-binding
pocket of MEKK1 might render MEKK1 resistant to modi-
fication by PEITC. We found that pre-loading the MEKK1
with the non-hydrolyzable ATP analog AMP-PNP, in vitro,
prior to PEITC exposure, protected MEKK1 from inhibi-
tion by PEITC (Figure 3, left panel). Again, the C1238V
mutant was resistant to PEITC (Figure 3, right). Thus
PEITC inhibition of MEKK1 requires both access to the
PEITC Inhibits MEKK1, but not ASK1 Figure 1
PEITC Inhibits MEKK1, but not ASK1. CV-1 cells expressing CBD-tagged full-length MEKK1 (left panel) or ASK1 (right 
panel) were either left untreated (lane 1 and 5) or treated with PEITC at the concentrations indicated (lanes 2–4 and 6–8 
respectively) for 30 minutes at 37°C. CBD-tagged proteins were purified on chitin beads and assayed for kinase activity using 
SEK-KR as substrate. MEKK1 was dose responsively inhibited by PEITC. The related ASK1 kinase was completely unaffected by 
PEITC, indicating that the inhibition of MEKK1 is specific.
ASK>
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12 34
<MEKK1
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100BMC Cancer 2007, 7:183 http://www.biomedcentral.com/1471-2407/7/183
Page 5 of 12
(page number not for citation purposes)
ATP-binding pocket of MEKK1 and the cysteine at posi-
tion 1238.
MEKK1 is covalently labeled by a new ITC probe: Biotin-
ITC
Using a modification of a published procedure [23], we
designed and synthesized an isothiocyanate molecule that
contained a biotin moiety, termed Bio-ITC, to enable spe-
cific detection and potential affinity purification of targets
of covalent ITC modification (Figure 4). The 1H NMR
spectrum was consistent with published data. Bio-ITC was
further characterized by 13C NMR and low-resolution
mass spectrometry.
Figure 5 demonstrates that Bio-ITC is functionally similar
to other isothiocyanates. Bio-ITC dose dependently inhib-
ited the activity of purified MEKK1 in vitro (Figure 5A,
top), without inhibiting the C1238V mutant (Figure 5A,
bottom). Bio-ITC covalently labeled MEKK1, since dose
dependent inhibition of MEKK1 (Figure 5B, top) resulted
in wild type MEKK1 that was labeled with biotin, as dem-
onstrated by detection with a streptavidin-enzyme conju-
gate (Figure 5B, middle). The C1238V mutant was neither
inhibited by Bio-ITC nor reactive with the streptavidin
conjugate. This demonstrates both that C1238 is required
for modification of MEKK1 by Bio-ITC, and also that none
of the other cysteines of MEKK1 can be stably modified by
Bio-ITC.
In contrast to the natural isothiocyanates, the charged Bio-
ITC was, as expected, poorly cell permeant. However, wild
type MEKK1, but not the C1238V mutant, was inhibited
by Bio-ITC in detergent-permeablized cell lysates (Figure
5C, lanes 3 and 6). The pattern of inhibition was similar
to that observed with the natural isothiocyanate, PEITC
(lanes 2 and 5).
AMP-PNP interferes with PEITC inhibition of MEKK1 Figure 3
AMP-PNP interferes with PEITC inhibition of 
MEKK1. MEKK1 catalytic domain fragment or the C1238V 
mutant were purified on chitin beads and then preincubated 
with 2 mM AMP-PNP/10 mM MgCl2 in 50 mM Tris pH7.8 for 
15 minutes at room temperature. PEITC was added to the 
reactions, and the incubations continued for an additional 30 
minutes. The bead bound proteins were then washed to 
remove the agents and kinase activity measured. Preincuba-
tion with AMP-PNP protected MEKK1 from inhibition by 
subsequent exposure to PEITC in vitro. The C1238V mutant 
was unaffected by any of the treatments.
AMP-PNP - + -
--
+
+ PEITC
wild type CV
+ - + -
--+
123 4 5 6 7
PEITC inhibits wild type MEKK1, but not the C1238V mutant  in cells and in vitro Figure 2
PEITC inhibits wild type MEKK1, but not the C1238V 
mutant in cells and in vitro. A. CV-1 cells expressing the 
catalytic domain fragment of wild type MEKK1 (top panel) or 
the C1238V mutant (bottom panel) were treated with PEITC 
at the indicated concentrations for 1 hour at 37°C. Kinases 
were purified on chitin beads and assayed for activity by in 
vitro kinase assay. B. Purified wild type MEKK1 (top panel) 
or the C1238V mutant (bottom panel) were treated with 
PEITC at the indicated concentrations for 30 minutes at 
room temperature. PEITC inhibited wild type MEKK1, but 
not the C1238V mutant both after treatment of intact cells 
and treatment of purified protein in vitro, indicating that the 
inhibition of MEKK1 is a direct effect on the kinase itself and 
requires the cysteine at position 1238.
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We used a blocking strategy to demonstrate the specificity
of in vitro labeling with Bio-ITC (Figure 6). Pretreatment
of intact cells with PEITC prior to preparation of the
lysates inhibited the kinase activity of the MEKK1 protein
and prevented subsequent in vitro labeling of wild type
MEKK1 by Bio-ITC (lane 5 middle and top panel, respec-
tively). As before, wild type MEKK1 but not C1238V
MEKK1 was inhibited in vitro by Bio-ITC (lanes 4 and 7,
middle panel), and wild type MEKK1 (but not C1238V
MEKK1) was covalently labeled with Bio-ITC (lanes 4 and
7, top panel). These results suggest that both Bio-ITC and
PEITC inhibit MEKK1 by direct modification in a manner
that requires the cysteine at position 1238.
PEITC specifically inhibits endogenous MEKK1 and 
downstream stress signaling kinases
We examined the effect of PEITC pretreatment on activa-
tion of endogenous MEKK1 by hyperosmotic shock in
LnCAP cells. These cells were chosen because they have
relatively high expression of MEKK1 in comparison to
other cell lines, allowing detection of the endogenous
protein activity by immunoprecipitation and in vitro
kinase assay. Hyperosmotic shock, induced by addition of
0.3 M sorbitol, strongly activated MEKK1 (Figure 7, upper
panel). Pretreatment of cells with PEITC dose-depend-
ently inhibited this activation, with complete inhibition
at the 50 µM dose, nearly complete inhibition at 25 µM,
and partial inhibition at 12.5 µM. This inhibition exactly
paralleled the effect of PEITC on SAPK activity in the same
lysates (Figure 7, lower panel). Thus PEITC blocks activa-
tion of MEKK1 by osmotic shock, and this inhibition
exactly correlates with inhibition of SAPK.
To test the specificity of PEITC in inhibiting the SAPK sig-
naling pathway, we examined the impact of PEITC pre-
treatment on the activation of other MAPKs by
hyperosmotic shock. As expected, we observed that PEITC
specifically inhibited the activating phosphorylation of
SAPK induced by hyperosmotic shock using sorbitol (Fig-
ure 8, Panel A), consistent with the inhibition seen by in
vitro kinase assay. In contrast, moderate concentrations of
PEITC had no effect on the sorbitol-induced phosphoryla-
tion and activation of the related MAPK family members,
ERK1/2 and p38 (Figure 8, Panel B and C, respectively).
We did observe fractional inhibition of p38 phosphoryla-
tion at the highest concentration of PEITC. However, p38
is substantially less sensitive to PEITC mediated inhibi-
tion than SAPK. Thus, inhibition of MEKK1 by PEITC spe-
cifically inhibits downstream stress signals leading to
SAPK, but not to other MAPK pathways.
Discussion
Our data show that both endogenous and plasmid-
expressed wild type MEKK1 are dose-dependently inhib-
ited by ITCs, through stable, direct covalent modification
in a manner requiring C1238. Signaling downstream of
endogenous MEKK1 is also specifically inhibited by
PEITC, since the MEKK1 target kinase, SAPK/JNK is inhib-
ited at similar doses, while ERK and p38 MAP kinases are
not inhibited. This result supports the conclusion that
SAPK activating pathways are specifically silenced by inhi-
bition of MEKK1 or similarly regulated kinases.
While the MEKK1-related kinase ASK1 is associated with
initiation of apoptotic pathways, MEKK1 itself is associ-
ated with anti-apoptotic responses [8,9]. This has been
confusing, since MEKK1 and ASK1 are thought to activate
similar if not identical downstream pathways. Specific
inhibition of MEKK1, but not ASK1, by PEITC is compat-
ible with the pro-apoptotic function of PEITC that might
be enabled by this differential effect on protein kinase
pathways.
Synthesis of Bio-ITC Figure 4
Synthesis of Bio-ITC. Norbiotinamine hydrochloride was converted to the isothiocyanate, Bio-ITC, by mild conditions 
with 1,1'-thiocarbonyldi-2,2'-pyridone (TCDP) in the presence of an amine base (Et3N). Synthesis and characterization are 
described in detail in the materials and methods.
HN NH
S
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BioITC inhibits MEKK1, but not the C1238V mutant, by covalent modification Figure 5
BioITC inhibits MEKK1, but not the C1238V mutant, by covalent modification. A. Purified MEKK1 or the C1238V 
mutant on chitin beads were treated with Bio-ITC at the concentrations indicated in 50 mM Tris pH7.8 for 40 minutes at room 
temperature. Bio-ITC was removed, and the kinase activity measured. Bio-ITC inhibits wild type MEKK1, but not the C1238V 
mutant in a dose dependent manner. B. Purified wild type MEKK1 or the C1238V mutant were treated as in Panel A with Bio-
ITC at the indicated concentrations. The treated protein was used to either assay for kinase activity (top panel) or to detect 
covalent modification by Bio-ITC using a streptavidin-HRP conjugate (middle panel). Equivalent protein was confirmed by re-
probing the streptavidin gel with anti-MEKK1 (bottom panel), using an alkaline phosphatase conjugated secondary antibody and 
colorimetric detection reagents. Bio-ITC inhibited wild type MEKK1 by stable, covalent modification in a manner that requires 
C1238V. C. CV-1 cells expressing either wild type MEKK1 or the C1238V mutant were lysed in Tris lysis buffer containing 
0.1% NP-40. Clarified lysates were treated by addition of either PEITC (P) or Bio-ITC (B) to final concentration of 250 µM, and 
incubated at room temperature for 30 minutes. MEKK1 proteins were purified on chitin beads and kinase activity measured. 
Both PEITC and Bio-ITC completely inhibited wild type MEKK1, but not the C1238V mutant when added to cell lysates.
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Inhibition of endogenous MEKK1 activity in intact LnCAP
cells requires a relatively high concentration of PEITC
compared to the dietary plasma levels in humans follow-
ing a single oral dose of ITCs (measured at about 2 µM
[14]). However, partial inhibition of MEKK1 at 12.5 µM,
with nearly complete inhibition at 25 µM and complete
abrogation at 50 µM, is remarkably similar to the dose
response reported in numerous studies examining apop-
totic effects of PEITC and correlating these effects with a
variety of markers of the apoptotic response [24-32].
Inhibition of MEKK1 activity within 30 minutes of PEITC
addition indicates that inhibition is a specific and acute
effect that is not due to protein loss that might accompany
measurements taken at later time points after apoptosis
had commenced. This is supported by equivalent recovery
of MEKK1 protein from the treated and untreated sam-
ples. In vitro inhibition of MEKK1 by PEITC also supports
a direct effect on catalytic activity, rather than a more com-
plicated mechanism of regulation involving protein deg-
radation or other regulators of MEKK1 function. Use of
the Bio-ITC probe conclusively establishes the mechanism
for this inhibition as covalent modification of C1238 (but
not other cysteines) of MEKK1.
Covalent modification of cellular proteins by ITCs has
been hypothesized previously. One group used indirect
assays to conclude that the Keap1 protein transiently
reacts with sulforaphane [33]. Since Keap1 is involved in
regulation of the activity of the Nrf2 transcription factor
that directs Phase 2 gene transcription from the promoter
element termed the antioxidant response element (ARE),
Keap1 is an attractive potential target for ITCs. However,
in this study, while spectrophotometric assays of absorb-
Covalent modification of MEKK1 by Bio-ITC is blocked by preincubation of cells with PEITC Figure 6
Covalent modification of MEKK1 by Bio-ITC is blocked by preincubation of cells with PEITC. CV-1 cells express-
ing wild type MEKK1 or the C1238V mutant were either left untreated or incubated with 250 µM PEITC for 20 minutes at 
37°C. Lysates were prepared in TLB, clarified and then 500 µM Bio-ITC was added to the samples as indicated. MEKK1 pro-
teins were purified from the lysates on chitin beads, and either electrophoresed for detection of biotin labeling using streptavi-
din-HRP (top panel) or assayed for kinase activity (middle panel). To confirm equivalent protein, the SA-HRP blot was re-
probed with anti-MEKK1 as in Figure 5. Lane 2 contains the molecular weight markers. Bio-ITC covalently modifies MEKK1 
protein and inhibits its activity in a manner that requires C1238V. The modification by Bio-ITC is completely inhibited by pre-
incubation of the cells with PEITC, suggesting that the modification site is completely occupied by the natural isothiocyanate 
after exposure of intact cells.
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ance shifts were used to support the conclusion that
Keap1 is modified by sulforaphane, no direct evidence
was presented for covalent labeling of Keap1. In addition,
these studies used purified recombinant Keap1 in vitro,
and no evidence was presented to support the ability of
sulforaphane to modify Keap1 in intact cells.
While the Keap1 study predicted that ITCs should make
readily-reversible reaction products with protein sulfhydr-
yls, our results with MEKK1 demonstrate stable products
that are resistant to heat, denaturants, and SDS used in
protein electrophoresis. While transient interaction of
ITCs with some protein thiols (as well as with glutath-
ione) likely occur in intact cells, stable covalent modifica-
tions of proteins are more likely to represent functional
targets, particularly at low ITC concentration. Our identi-
fication of MEKK1 as a functional target of ITCs points the
way to an understanding of a general mechanism of ITCs
and other bioactive electrophiles. It remains unproven
whether modification and inhibition of MEKK1 plays a
singular role in the effects of ITCs in apoptosis or cancer
chemoprevention. We suspect that MEKK1 is one of sev-
eral or many cellular targets that contribute to the multi-
ple effects of ITCs. Identification of these targets and
characterization of their relative role(s) in the transcrip-
tional, cell growth and apoptosis pathways induced by
ITCs is an important goal for future studies. We are cur-
rently using our Bio-ITC reagent and affinity chromatog-
raphy to identify other stably modified proteins that
PEITC inhibits endogenous MEKK1 and downstream signaling to SAPK Figure 7
PEITC inhibits endogenous MEKK1 and downstream signaling to SAPK. LNCaP cells were incubated with PEITC at 
the indicated concentrations for 15 minutes at 37°C. Hyperosmotic shock was induced by addition of sorbitol to a final con-
centration of 300 mM and cells were incubated for an additional 15 min. Lysates were prepared, MEKK1 and SAPK were iso-
lated by immunoprecipitation and their activity was measured by in vitro kinase assay with SEK-KR (MEKK1, upper panel) or 
jun (SAPK, lower panel) as substrate. Activation of endogenous MEKK1 by hyperosmotic shock was dose dependently inhib-
ited by PEITC pretreatment. The inhibition of MEKK1 exactly paralleled inhibition of SAPK.
–
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could, as a whole, explain the means through which these
dietary constituents prevent cancer.
After the completion of this work, reports were published
that ITCs and other thiol reactive electrophilic com-
pounds are able to covalently modify and activate the
TRPA1 ion channel involved in pain sensing [34,35]. The
two groups disagreed about whether the modifications
were reversible and which cysteines were required for the
modification, and neither group considered the potential
role of this protein target in chemoprevention. However,
these data provide an additional model for ITCs specifi-
cally and covalently modifying protein targets on cysteine
residues, supporting our contention that direct modifica-
tion of protein targets by dietary ITCs may play an impor-
tant role in their chemopreventive activity. We expect that
several covalent targets of ITCs may together contribute to
PEITC specifically interferes with downstream signaling to SAPK/JNK Figure 8
PEITC specifically interferes with downstream signaling to SAPK/JNK. HeLa cells were incubated with PEITC at the 
indicated concentrations for 7 minutes at 37°C. Hyperosmotic shock was induced by addition of sorbitol to a final concentra-
tion of 400 mM, and the cells incubated for an additional 20 minutes. Cell lysates were analyzed by immunoblotting with anti-
bodies for phosphorylated forms of the MAPKs as indicated to the right. Duplicate gels were probed with antibodies to each 
MAPK, to confirm equivalent protein expression. PEITC interferes with the activation of SAPK, but not ERK or p38, in a dose 
dependent manner.
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the multiple biological functions of these important nutri-
tional components.
Conclusion
Our results provide new insights into the molecular
actions of dietary isothiocyanates. ITCs directly and cova-
lently modify at least one cell signaling protein within
cells, resulting in the functional silencing of the MEKK1
protein kinase and blockade of SAPK/JNK signaling. Our
results do not preclude ITCs having other functional tar-
gets in cells that may contribute to the pleiotropic func-
tions of these nutritional compounds. However, we
predict that all cellular targets of ITCs will parallel the
mechanism of MEKK1 inactivation, i.e. through stable
covalent modification resulting in altered protein func-
tion.
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